Studies establishing that intermittent sc interleukin-2 (IL-2) therapy can lead to substantial CD4 cell increases in many HIV-infected patients have generally been of limited duration. We studied 77 patients participating in active longitudinal studies of sc IL-2 therapy at our center in order to determine the long -term feasibility of this approach. Following initial induction, patients in each trial were eligible to receive intermittent 5-day cycles of sc IL-2 treatment at individualized doses and frequencies capable of maintaining CD4 counts at postinduction levels. The mean duration of study participation to date is 5.9 (range:
Introduction
While initially developed and ultimately licensed in the United States for the therapy of specific forms of refractory malignancy, interleukin-2 treatment has also been studied in the context of reversing the immunologic effects of HIV-1 infection. 1 Indeed, experimental treatment of HIV-infected individuals with interleukin-2 (IL-2) in various forms has been under study in this country since the early 1980's even prior to the etiologic identification of AIDS. 2 Over the ensuing years, but in particular since the early 1990's, a robust international phase II database of intermittent IL-2 treatment experience has accumulated. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] This database provides strong evidence that, for many patients receiving concurrent antiretroviral therapy (ART), an unprecedented rise in CD4+ cell counts can occur as a consequence of a scheduled series of intermittent IL-2 treatment cycles. Building upon these observations, the international phase III SILCAAT and ESPRIT trials were launched and are currently exploring whether these CD4 count changes translate into demonstrable clinical benefit for IL-2 recipients. 16, 17 While these endpoint trials are ongoing, an acknowledged limitation of the current database is that most published studies to date have involved fairly limited treatment schedules without extensive long-term follow-up. For this reason most clinicians remain familiar with only the short-term effects of IL-2 therapy and have little direct knowledge of how this agent could potentially be employed within the context of a long-term treatment strategy.
In this report we summarize our long-term experience with three cohorts of HIV-infected individuals and their longitudinal response to IL-2 therapy. We explore, in particular, whether an "induction-maintenance" model using this cytokine can reasonably be applied to the overall management of these patients.
Methods
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Patients included in this analysis were those who had enrolled in the extension phase of three separate trials of subcutaneous IL-2 plus ART. The initial phase of each trial had a distinct study design, dose and schedule of sc IL-2 administration, and entry CD4 cell count requirement (Table 1) . These trials enrolled patients during a time period spanning 1993 through early 1997.
The first subcutaneous IL-2 trial ("sc IL-2") was designed as an initial 12-month, dose escalating study aimed at determining the maximum tolerated dose for sc IL-2 in patients with CD4 counts 200 cells/microLiter. 4 Eighteen patients were enrolled between 9/14/93 and 6/7/94. The second subcutaneous IL-2 trial Immunologic and virologic (bDNA assay version 3.0, Bayer Diagnostics, Tarrytown, NY) assessments were performed a s previously described. 5 For analytical purposes, all viral loads below the lower limit of detection (< 50 copies/ml.) were assigned a value of 49 copies/ml.
Results
Of a total of 97 patients originally enrolled in the 3 trials, 77 patients continued to receive sc IL-2 treatment during the extension phase of each study.
Of the 20 patients who did not continue IL-2 therapy, 2 were enrolled in the original study but subsequently declined participation following randomization, 10
did not complete the formal study period, 7 chose to discontinue participation after the formal study period, and 1 never received any IL-2 treatment ( Figure 1 ).
61 patients currently remain on active follow-up. Four patients in this cohort were diagnosed with an AIDS-defining condition at some point during their study participation (Table 2) There was a corresponding drop in mean CD8% as the mean CD4% rose, while absolute CD8 counts changed only slightly: mean CD8% declined from 53% at study entry to 42% at 90 months, whereas the mean CD8 cell count [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] % over this same time period. Similar, both naïve (RO-) and memory (RO+) phenotype expression on CD4+ cells was induced by IL-2: mean RO+ CD45% rose from 17% at study entry to 23% at month 90, while mean RO-CD45% rose from 10% at study entry to 14% at month 90 ( Figure 4 ).
Corresponding median [25%-75% IQR] values for RO+ CD45% were 16 [13] [14] [15] [16] [17] [18] [19] [20] % and 22 [18- Viral load did not increase in study participants during the extension period. Using the bDNA version 3.0 assay, the mean HIV log VL at baseline was 3.53 log copies/mL and declined to 2.61 log copies/mL at 90 months ( Figure 5 ). The potential effects of patient attrition were examined by assigning baseline CD4 values as maximums to all subsequent data points for each patient of the original 97 for whom follow-up data were unavailable. The mean CD4 counts at 48 weeks and at 78 weeks using this method would be 867 and 751 Clinical endpoints for this patient population were defined as AIDSdefining illnesses or death. One patient with long-standing short term memory loss was diagnosed with possible mild HIV encephalopathy. Two patients developed cutaneous Kaposi sarcoma and, as mentioned above, one patient was diagnosed with Non-Hodgkin's lymphoma (Table 2) . Three patient deaths were reported: two patients, both IL-2 non-responders, died of opportunistic infections prior to completion of the initial study phase, and one patient on the extension phase died from cardiac disease two years after study discontinuation.
12 patients enrolled in the extension phase were diagnosed with either subclinical or mild clinical hypothyroidism; 10 of these patients received synthetic thyroid hormone treatment at some point during their participation. 
